Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
May 13 2024 - 5:00AM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today announced
the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI
supercomputer, powered by 63 DGX H100 systems with a total of 504
NVIDIA H100 Tensor Core GPUs interconnected by NVIDIA Quantum-2
InfiniBand networking. This NVIDIA-powered AI supercomputer results
in four times faster speeds than Recursion’s original
supercomputer, BioHive-1, in benchmark performance tests. Based on
available data, BioHive-2 is the fastest supercomputer wholly owned
and operated by any pharmaceutical company worldwide.
"Scaled data generation paired with scaled computation is
required to leverage AI in a space as vast and complex as biology,”
said Ben Mabey, Chief Technology Officer at Recursion. “Recursion
has spent the last decade generating and aggregating one of the
largest biological and chemical datasets in the world,
purpose-built for training new AI models. With BioHive-2 now
online, we have significantly more computational horsepower to
accelerate our use of our ever-growing dataset, extending our
ability to train larger and more generalizable foundation models
and AI agents to industrialize our drug discovery efforts.”
Recursion has demonstrated the importance of scaled computation
by developing groundbreaking new foundation models like Phenom-1, a
deep-learning model designed to extract biologically meaningful
features from images of cells. As Recursion increased the size of
the training data and the number of model parameters, the model’s
performance increased, demonstrating a need for ample compute to
train larger models. The experimentation and training to produce
Phenom-1 required several months of computational time on
BioHive-1. With BioHive-2, multiple ambitious AI projects of
similar or greater size could be executed in parallel in shorter
timeframes, enabling both the Recursion and Valence Labs teams to
push on the frontier of AI in drug discovery and unlock the latent
value of Recursion’s data.
A smaller model similar to Phenom-1, called Phenom-Beta, has
been released for external use on the NVIDIA BioNeMo platform. The
Phenom series is just one of several different models Recursion has
developed to accelerate the drug discovery process using
biological, chemical, and real-world patient data. Phenom-Beta is
the first third-party model to be made available on the BioNeMo
platform.
“Accelerated computing, combined with the power of generative
AI, is propelling the pharmaceutical industry into a new, advanced
era of drug discovery,” said Rory Kelleher, global head of business
development for life sciences at NVIDIA. “BioHive-2, powered by
NVIDIA DGX AI supercomputing, is poised to accelerate the
development of additional industry-leading foundation models across
biology, chemistry, and healthcare.”
Other achievements that relied on Recursion’s platform, powered
by NVIDIA accelerated computing, include the massive protein-ligand
interaction prediction dataset announced last year. Recursion
predicted the protein target(s) for approximately 36 billion
chemical compounds in the Enamine REAL Space. As a result of this
significant computational accomplishment, Recursion and Enamine
have formed a collaboration to generate enriched compound libraries
for the global drug discovery industry.
About RecursionRecursion is a clinical stage
TechBio company leading the space by decoding biology to
industrialize drug discovery. Enabling its mission is the Recursion
OS, a platform built across diverse technologies that continuously
expands one of the world’s largest proprietary biological, chemical
and patient-centric datasets. Recursion leverages sophisticated
machine-learning algorithms to distill from its dataset a
collection of trillions of searchable relationships across biology
and chemistry unconstrained by human bias. By commanding massive
experimental scale — up to millions of wet lab experiments weekly —
and massive computational scale — owning and operating one of the
most powerful supercomputers in the world, Recursion is uniting
technology, biology, chemistry and patient-centric data to advance
the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerly Twitter) and LinkedIn.
Forward-Looking StatementsThis document
contains information that includes or is based upon
"forward-looking statements'' within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation, those
regarding expectations related to the performance of the BioHive-2
supercomputer and its impact on our operations and the drug
discovery process; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as “plan,” “will,” “expect,” “anticipate,”
“intend,” “believe,” “potential,” “could,” “continue,” and similar
terms. These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; inflation and other macroeconomic issues; and other
risks and uncertainties such as those described under the heading
“Risk Factors” in our filings with the U.S. Securities and Exchange
Commission, including our most recent Quarterly Report on Form 10-Q
and our Annual Report on Form 10-K for the Fiscal Year Ended
December 31, 2023. All forward-looking statements are based on
management’s current estimates, projections, and assumptions, and
Recursion undertakes no obligation to correct or update any such
statements, whether as a result of new information, future
developments, or otherwise, except to the extent required by
applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024